HEALTH OF WOMAN. 2016.9(115):78–85; doi 10.15574/HW.2016.115.78 
 

Individualisation treatment of patients with epithelial ovarian tumors in view of the clinical-morphological signs and additional definition of immunohistochemistry markers

Nespradko S. V., Melnyk M. M., Goncharuk I. V.

National cancer Institute, MH Ukraine, Kyiv

National children's specialized hospital «OKHMATDYT» of the MOH of Ukraine, Kyiv

The complexity of clinical diagnosis (asyptomatic) of epithelial ovarian tumors and large number of morphological (histological) types of their structure requires in modern conditions applying additional immunohistochemical markers that allows you to individualization the treatment tactics and determine prognosis.

The objective: to determine immunohistochemical markers (ER, PR, p53, Ki-67, CD34, E-cadherin) in tumors of the ovaries for individualization treatment and prognosis.

Patients and methods. Ovarian neoplasms among 30 patients. Morphological and histological immunohistochemical methods.

Results. The largest part of our study of ovarian endometrioid cyst neoplasms amounted to – 15 cases (50%), serous cyst 4 cases (14%), serous borderline tumors-3 cases (10%), the serous borderline malignancy tumor of type well differentiated serous adenocarcinoma GI-II–1 (3%), a case of mucinous cyst – 1 (3%) case, borderline mucinous tumor – 3 (10%) case 2 (7%) case combination of endometrioid and serous cysts, 1 (3%) case-mature dermoid cyst.

Receptors of estrogen, progesterone and the proliferation marker Ki-67 are key predictive markers, high rate of 70% and the first low rate of less proliferation than 10% indicates a favorable prognosis and lets you customize the hormonal treatment with serous and endometrioid cysts, particular more favourable cases when border serous cysts.

Mutant protein p53 helps to determine, in particular in the group of borderline serous and mucinos tumor adverse events which are subject to active monitoring and clinical application of preventive chemotherapy.

Cell adhesion marker E-cadherin had practical significance in differential diagnosis, in particular for rendering the epithelial lining in endometrioid cysts, the absolute correlation decrease cell adhesion (intensity expression) is not detected in different histological types (factor into «true» membrane and atypical expression in the cytoplasm), antigen CD34 also, marker of vascular density did not have applied practical significance due to cystic ovarian neoplasm morphological structure, lack of unified field measuring micro-vessels.

Conclusion: neoplasm the ovaries along with the classical histological method of advisable include immunohistochemistry markers, which allow you to more accurately determine their biological nature, improve diagnostics, individualized treatment and tactics determine prognosis.

Key words: epithelial ovarian tumors, diagnosis, treatment, immuhistochemical method.

REFERENCES

1. Antoneeva II. 2004. Expression of antigens of human papillomavirus, Herpes Simplex and phenotype of estrogen and progesterone receptors in malignant epithelial ovarian tumors: Manuscript . Thesis for scientific degree of the candidate of medical sciences in speciality 14.00.14 Oncology. St. Petersburg 96.

2. Babichenko II, Kovyazin VA. 2008. New methods immunohistochemical diagnosis of tumor growth: Stud. allowance. М, INSTITUTE 109.

3. Bohman Y. 2002. Manual of oncogynecology. St. Petersburg: «OOO Izdatelstvo Folliant» 542.

4. Garin AM, Bathin IS. 2006. «The ten most common malignant tumors» 89.

5. Glazunov MF. 1954. Ovarian tumors (morphology, histogenesis, pathogenesis)Ed.,Medgiz. 323.

6. Naninec Nl. 2008. Clinico-morphological criteria those border (proliferating) epithelial ovarian tumors and prognosis for patients: Manuscript . Thesis for scientific degree of the candidate of medical sciences in speciality 14.00.15. Patology anatomy. St. Petersburg 89.

7. Repin NB. 2005. Clinico-morphological and immunohistochemical characterization of serous ovarian tumors: Manuscript . Thesis for scientific degree of the candidate of medical sciences in speciality 14.00.14 Oncology. Ryzan 17.

8. Tkalya YG. 2015. Patogenesis gormonal treatment maligna tumor of the ovarii Manuscript . Thesis for scientific degree of the candidate of medical sciences in speciality. 01.13.07. Oncology. Kiev 27.

9. Shubin VP. 2011. Molecular-genetic analysis of structure and BRCA1/2 genes in ovarian cancer and breast cancer: Manuscript. Thesis for scientific degree of the candidate of biological sciences: 03.02.07 Genetics. Moscow:119.

10. Grandi G, Toss A, Cortesi L, Botticelli L et al. 2015, Feb. The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life. BioMed Researc International. 8:10. https://doi.org/10.1155/2015/751571

11. Farooq S, Tasleem R, Nazir N et al. 2013, Nov. Histopathological pattern of ovarian neoplasms and estrogen and progesterone receptor expression in primary epithelial tumours and their histopathological correlation. Int. J. Cur. Res. Rev. 5(21):70 – 77.

12. Khandakar B, Mathur RS, Kumar L et al. 2010, April. Tissue Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant Chemotherapy. BioMed. Research. International. 8:9.

13. Le Page Cйcile, Huntsman GD, Provencher MD et al. 2010, May. Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies (Review). 2:913-54.

14. Nicoleta GL, Ungureanus C, Sultana MM. 2012, Nov. The immunohistochemical expression of p53 and Ki67 in ovarian epithelial borderline tumors. Correlation with clinicopathological factors. Rom. J. Morphol. Embryol. 53(4):967–73.

15. Ozer Н, Yenicesu G, Arici S et al. 2012, April. Immunohistochemistry with apoptoticantiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors. Diagnostic Pathology 7(1):124. https://doi.org/10.1186/1746-1596-7-124; PMid:22995373 PMCid:PMC3523067